Figure 2.

ITPA genetic polymorphism and PEG-IFN/RBV-induced anemia. (A) ITPA genetic polymorphism and Hb decline at 4 weeks after initiation of therapy among patients with HCV-induced cirrhosis. (B) ITPA genetic polymorphism and treatment-induced anemia in Spx and non-Spx groups. (C) The changes of Hb levels among ITPA major carriers in the comparison of Spx and non-Spx groups.

Motomura et al. BMC Gastroenterology 2012 12:158   doi:10.1186/1471-230X-12-158
Download authors' original image